The findings of this PSM study showed that first-line treatment with chemotherapy combined with ICIs significantly improved PFS in patients with HER-2 negative advanced gastric cancer; however, there was no significant improvement in OS, and the side effects were tolerable. The gene discussed is ERBB2; the disease is gastric cancer.